LAUSR

Objectives Bevacizumab, an anti-vascular endothelial growth factor antibody with chemotherapy improved the progression-free survival (PFS) in relapsed ovarian cancer. There is a paucity of data regarding the use of bevacizumab from the Indian subcontinent. Methods We retrospectively reviewed the clinical data of patients with epithelial ovarian cancer (EOC) from the hospital database treated during 2016–2019. The progression-free survival (PFS), overall response rate (ORR) and toxicity profile analysed using IBM SPSS software version 25.0 (IBM Corp., Armonk, NY). Results Sixty-two women with relapsed ovarian cancer were treated with bevacizumab (15mg/kg) and chemotherapy. The median age was 60 years (IQR 36–64). Platinum sensitive (PS) relapse constitutes 38/61(62.3%) and platinum resistant (PR) disease in 23/61(37.7%). The ORR in PS and PR groups are 59% and 26% respectively. Compared with the PR group, the PS group achieved a significantly longer one-year PFS (64% vs 9.3%, P<0.004). The toxicity profile is not statistically significant between the two groups. Abstract 297 Figure 1 Progression free survival Abstract 297 Table 1 Toxicity Platinum Sensitive Ca Ovary Platinum Resistant Ca Ovary Hypertension Any Grade 25/38(65.7%) 14/23(60.8%) Proteinuria Any Grade 5/38(13.1%) 5/23(21.7%) Bleeding Any Grade 12/38(31.5%) 7/23(30.4%) Intestinal Perforation Any Grade 1/38(2.6%) 2/23(8.6%) Soft Tissue Infection 5/38(13.1%) 1/23(4.3%) Hand Feet Syndrome Any Grade 0/38(0%) 3/23(13%) Anaemia Grade 3/4 4/38(10.5%) 2/23(8.6%) Neutropenia Grade 3/4 10/38(26.3%) 7/23(30.4%) Thrombocytopenia Grade 3/4 1/38 2/23(8.6%) Conclusions The present study is the first Indian data on the outcome of relapsed ovarian cancer treated with bevacizumab-based therapy. Progression-free survival significantly higher in platinum-sensitive ca ovary patients as compared to platinum-resistant patients with an acceptable toxicity profile.